Klin Farmakol Farm. 2006;20(3):162-164
NEWS IN THE TREATMENT OF THE ADVANCED HEAD AND NECK TUMOURS
- Chirurgická klinika FN Plzeň
Head and neck tumours are conditions in which the outcome of therapy is determined by the ability to achieve locoregional control of the tumour. The treatment of an advanced head and neck tumour with radiochemotherapy produces a good therapeutic response, however, in 40 percent of patients recurrence occurs. Concurrent administration of cetuximab and radiotherapy in advanced carcinomas of this region significantly prolongs time to progression (from 14.9 months to 24.4 months). A combination of cetuximab and chemotherapy in relapsing disease following primary therapy extends survival by 2.5 months.
Keywords: Key words: head and neck tumours, chemotherapy, radiotherapy, biological therapy.
Published: January 1, 2007 Show citation
References
- Bonner JA, Harari PM, Giralt J, Baselga J, Shin D, Cohen R, Jassem J, Azarnia N, Molloy P, Ang KK. Improved Preservation of Larynx with the Addition of Cetuximab to Radiation for Cancers of the Larynx and Hypopharynx, ASCO 2005: Abstrakt No 5533.
Go to original source... - Vermorken J, Bourhis J, Trigo J, Kies M, Leon X, Mueser M, N Amellal, Schueler A. J. Baselga Cetuximab (Erbitux(R)) in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies, ASCO 2005: Abstrakt No 5505. Go to original source...
- Bonner JA, Harari PM, Goraly J, et al. Radiotherapy plus cetuximab for squamous -cell carcinoma of the head and neck. N Engl J Med 2006 Feb 9; 354 (6): 634-636. Go to original source...
Go to PubMed...